155 related articles for article (PubMed ID: 23319326)
21. Crystal structure of the nucleotide-binding domain of mortalin, the mitochondrial Hsp70 chaperone.
Amick J; Schlanger SE; Wachnowsky C; Moseng MA; Emerson CC; Dare M; Luo WI; Ithychanda SS; Nix JC; Cowan JA; Page RC; Misra S
Protein Sci; 2014 Jun; 23(6):833-42. PubMed ID: 24687350
[TBL] [Abstract][Full Text] [Related]
22. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins--identification of additional interacting regions.
Iosefson O; Azem A
FEBS Lett; 2010 Mar; 584(6):1080-4. PubMed ID: 20153329
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of plasma ORM2 levels in patients with stage II colorectal cancer.
Gao F; Zhang X; Whang S; Zheng C
Ann Clin Lab Sci; 2014; 44(4):388-93. PubMed ID: 25361921
[TBL] [Abstract][Full Text] [Related]
24. Involvement of mortalin in cellular senescence from the perspective of its mitochondrial import, chaperone, and oxidative stress management functions.
Yaguchi T; Aida S; Kaul SC; Wadhwa R
Ann N Y Acad Sci; 2007 Apr; 1100():306-11. PubMed ID: 17460192
[TBL] [Abstract][Full Text] [Related]
25. Serum Mortalin Correlated with α-Synuclein as Serum Markers in Parkinson's Disease: A Pilot Study.
Singh AP; Bajaj T; Gupta D; Singh SB; Chakrawarty A; Goyal V; Dey AB; Dey S
Neuromolecular Med; 2018 Mar; 20(1):83-89. PubMed ID: 29307058
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of mitochondrial permeability transition pore opening is involved in the protective effects of mortalin overexpression against beta-amyloid-induced apoptosis in SH-SY5Y cells.
Qu M; Zhou Z; Chen C; Li M; Pei L; Yang J; Wang Y; Li L; Liu C; Zhang G; Yu Z; Wang D
Neurosci Res; 2012 Jan; 72(1):94-102. PubMed ID: 22001761
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of mortalin expression reverses cisplatin resistance and attenuates growth of ovarian cancer cells.
Yang L; Li H; Jiang Y; Zuo J; Liu W
Cancer Lett; 2013 Aug; 336(1):213-21. PubMed ID: 23665506
[TBL] [Abstract][Full Text] [Related]
28. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
[TBL] [Abstract][Full Text] [Related]
29. Mortalin - a multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration.
Flachbartová Z; Kovacech B
Acta Virol; 2013; 57(1):3-15. PubMed ID: 23530819
[TBL] [Abstract][Full Text] [Related]
30. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.
Kos J; Nielsen HJ; Krasovec M; Christensen IJ; Cimerman N; Stephens RW; Brünner N
Clin Cancer Res; 1998 Jun; 4(6):1511-6. PubMed ID: 9626470
[TBL] [Abstract][Full Text] [Related]
31. Partner of Sld five 3: a potential prognostic biomarker for colorectal cancer.
Sun X; Sui W; Huang M; Wang Y; Xuan Y; Wang Z
Diagn Pathol; 2014 Nov; 9():217. PubMed ID: 25403684
[TBL] [Abstract][Full Text] [Related]
32. Mortalin mutations are not a frequent cause of early-onset Parkinson disease.
Freimann K; Zschiedrich K; Brüggemann N; Grünewald A; Pawlack H; Hagenah J; Lohmann K; Klein C; Westenberger A
Neurobiol Aging; 2013 Nov; 34(11):2694.e19-20. PubMed ID: 23831374
[TBL] [Abstract][Full Text] [Related]
33. Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.
Shankaranarayana AH; Meduri B; Pujar GV; Hariharapura RC; Sethu AK; Singh M; Bidye D
Future Med Chem; 2023 Nov; 15(22):2087-2112. PubMed ID: 37877348
[TBL] [Abstract][Full Text] [Related]
34. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H
Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
[TBL] [Abstract][Full Text] [Related]
36. SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.
Huang MB; Wu JY; Lillard J; Bond VC
Oncotarget; 2019 Sep; 10(52):5419-5438. PubMed ID: 31534628
[No Abstract] [Full Text] [Related]
37. Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarcinoma--immunohistochemistry and Western blot analysis.
Milićević ZT; Petković MZ; Drndarević NC; Pavlović MD; Todorović VN
Neoplasma; 2007; 54(1):37-45. PubMed ID: 17233550
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis.
Wadhwa R; Takano S; Kaur K; Deocaris CC; Pereira-Smith OM; Reddel RR; Kaul SC
Int J Cancer; 2006 Jun; 118(12):2973-80. PubMed ID: 16425258
[TBL] [Abstract][Full Text] [Related]
39. Serum level of soluble 70-kD heat shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis.
Kocsis J; Madaras B; Tóth EK; Füst G; Prohászka Z
Cell Stress Chaperones; 2010 Mar; 15(2):143-51. PubMed ID: 19578980
[TBL] [Abstract][Full Text] [Related]
40. Elevated serum levels of heat shock protein 70 are associated with breast cancer.
Gunaldi M; Afsar CU; Okuturlar Y; Gedikbasi A; Kocoglu H; Kural A; Akarsu C; Gunduz U; Tiken EE
Tohoku J Exp Med; 2015 Jun; 236(2):97-102. PubMed ID: 26018606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
